1. Home
  2. RENEU vs GNLX Comparison

RENEU vs GNLX Comparison

Compare RENEU & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RENEU
  • GNLX
  • Stock Information
  • Founded
  • RENEU N/A
  • GNLX 2001
  • Country
  • RENEU
  • GNLX United States
  • Employees
  • RENEU 2
  • GNLX N/A
  • Industry
  • RENEU
  • GNLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RENEU
  • GNLX Health Care
  • Exchange
  • RENEU NYSE
  • GNLX Nasdaq
  • Market Cap
  • RENEU N/A
  • GNLX 107.1M
  • IPO Year
  • RENEU N/A
  • GNLX 2023
  • Fundamental
  • Price
  • RENEU $11.38
  • GNLX $3.13
  • Analyst Decision
  • RENEU
  • GNLX Strong Buy
  • Analyst Count
  • RENEU 0
  • GNLX 4
  • Target Price
  • RENEU N/A
  • GNLX $18.75
  • AVG Volume (30 Days)
  • RENEU N/A
  • GNLX 173.5K
  • Earning Date
  • RENEU N/A
  • GNLX 11-12-2024
  • Dividend Yield
  • RENEU N/A
  • GNLX N/A
  • EPS Growth
  • RENEU N/A
  • GNLX N/A
  • EPS
  • RENEU N/A
  • GNLX N/A
  • Revenue
  • RENEU N/A
  • GNLX $8,000.00
  • Revenue This Year
  • RENEU N/A
  • GNLX N/A
  • Revenue Next Year
  • RENEU N/A
  • GNLX N/A
  • P/E Ratio
  • RENEU N/A
  • GNLX N/A
  • Revenue Growth
  • RENEU N/A
  • GNLX N/A
  • 52 Week Low
  • RENEU N/A
  • GNLX $1.60
  • 52 Week High
  • RENEU N/A
  • GNLX $18.01
  • Technical
  • Relative Strength Index (RSI)
  • RENEU 44.51
  • GNLX 66.29
  • Support Level
  • RENEU $11.37
  • GNLX $2.98
  • Resistance Level
  • RENEU $11.60
  • GNLX $3.50
  • Average True Range (ATR)
  • RENEU 0.00
  • GNLX 0.33
  • MACD
  • RENEU 0.00
  • GNLX 0.06
  • Stochastic Oscillator
  • RENEU 0.00
  • GNLX 73.97

About RENEU CARTESIAN GROWTH CORPORATION II UNIT COM 1 CL A & 1/3 WT EXP(12/07/2028)

Cartesian Growth Corp II is a blank check company.

About GNLX Genelux Corporation

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Share on Social Networks: